DeepMed Research

Takeda Pharmaceutical Company Ltd

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 4, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: SYR-472
Drug: Placebo

First Posted Date: 2014-12-24

Last Posted Date: 2023-12-12

Lead Sponsor: Takeda

Target Recruit Count: 240

Registration Number: NCT02324569

A Phase 1, Single and Multiple Dose Study of TAK-137

Phase 1

Withdrawn

Conditions: Healthy Japanese Adult Male

Interventions: Drug: TAK-137 5 mg tablet, TAK-137 placebo tablet
Drug: TAK-137 5mg tablet, TAK-137 placebo tablet
Drug: TAK-137 5 mg tablet, TAK-137 placebo tablet or TAK-137 0.5 mg tablet, TAK-137 placebo tablet

First Posted Date: 2014-12-23

Last Posted Date: 2015-11-26

Lead Sponsor: Takeda

Registration Number: NCT02322606

Phase 1/2 Study of TAK-850 Subcutaneous Injection in Healthy Adults

Phase 1

Completed

Conditions: Influenza Infection

Interventions: Drug: Subcutaneous injection of TAK-850
Drug: Intramuscular injection of TAK-850

First Posted Date: 2014-12-09

Last Posted Date: 2016-02-17

Lead Sponsor: Takeda

Target Recruit Count: 110

Registration Number: NCT02313155

A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Placebo
Drug: Ixazomib

First Posted Date: 2014-12-09

Last Posted Date: 2023-09-21

Lead Sponsor: Takeda

Target Recruit Count: 706

Registration Number: NCT02312258

Locations: 🇧🇷
Clinica Sao Germano, Sao Paulo, Brazil
🇺🇸
North County Oncology Medical Clinic Inc, Oceanside, California, United States
🇦🇷
Centro de Educacion Medica e Investigaciones Clinicas "Norberto Quirno" (CEMIC), Buenos Aires, Ciudad Autonoma De BuenosAires, Argentina

and more 270 locations

Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants

Phase 2

Completed

Conditions: Dengue Fever

Interventions: Biological: Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
Biological: TDV Placebo

First Posted Date: 2014-11-26

Last Posted Date: 2020-02-24

Lead Sponsor: Takeda

Target Recruit Count: 1800

Registration Number: NCT02302066

Locations: 🇵🇭
Dela Salle Health Sciences Institute, Dasmarinas, Cavite, Philippines
🇩🇴
Hospital Maternidad Nuestra Senora de la Altagracia, Santo Domingo, Distrito Nacional Santo Domingo, Dominican Republic
🇵🇦
Centro De Vacunacion Internacional, S.A.(CEVAXIN), Ciudad de Panama, Panama

An Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Participants With Urinary Tract Infections

Phase 3

Terminated

Conditions: Urinary Tract Infection

Interventions: Drug: Flomoxef
Drug: Cefepime

First Posted Date: 2014-11-26

Last Posted Date: 2017-10-27

Lead Sponsor: Takeda

Target Recruit Count: 13

Registration Number: NCT02302092

Postmarketing Clinical Study on AO-128

Phase 4

Completed

Conditions: Impaired Glucose Tolerance (IGT)

Interventions: Drug: AO-128

First Posted Date: 2014-11-10

Last Posted Date: 2015-04-09

Lead Sponsor: Takeda

Target Recruit Count: 197

Registration Number: NCT02287402

TAK-114 Single- and Multiple-Dose Phase 1 Study

Phase 1

Completed

Conditions: Clinical Pharmacology

Interventions: Drug: TAK-114 10 mg capsule
Drug: TAK-114 matched placebo

First Posted Date: 2014-11-07

Last Posted Date: 2016-07-25

Lead Sponsor: Takeda

Target Recruit Count: 82

Registration Number: NCT02286518

Specified Drug-use Survey of the Granular Capsule Formulation of Omega-3 Fatty Acid Ethyl Esters: OCEAN3

Completed

Conditions: Hyperlipidemia

Interventions: Drug: Standard antihyperlipidemic therapy other than administration of omega-3 fatty acid ethyl esters (Lotriga).
Drug: Omega-3 fatty acid ethyl esters

First Posted Date: 2014-11-06

Last Posted Date: 2022-02-18

Lead Sponsor: Takeda

Target Recruit Count: 15330

Registration Number: NCT02285166

AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease

Phase 3

Terminated

Conditions: Mild Cognitive Impairment Due to Alzheimer's Disease

Interventions: Drug: Pioglitazone
Drug: Placebo

First Posted Date: 2014-11-06

Last Posted Date: 2019-07-02

Lead Sponsor: Takeda

Target Recruit Count: 40

Registration Number: NCT02284906

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy